Previous studies have shown that co-mutations of TP53 and KRAS can function as potential biomarkers for immune checkpoint blockade in lung cancer (40) and that co-mutations of KRAS and TP53 could identify long-term responders to first-line palliative treatment with pembrolizumab from patients with LUAD with high PD-L1 level (41). Here, KRAS is linked to lung cancer.